TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Telomir Pharmaceuticals, Inc. ( (TELO) ) has shared an update.
Telomir Pharmaceuticals announced that their compound, Telomir-1, has shown in vitro efficacy in targeting the KDM5 histone demethylase family, adding to its previously known activity against KDM2/KDM6 and DNA methylation. This broad-spectrum activity positions Telomir-1 as a potentially groundbreaking epigenetic therapy, with implications for treating aggressive cancers and age-related conditions by reactivating tumor suppressors and preventing harmful gene silencing.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing epigenetic therapies for cancer and aging. The company is known for its innovative approach to targeting histone demethylase families and DNA methylation, aiming to address unmet needs in cancer treatment and age-related diseases.
Average Trading Volume: 4,654,855
Technical Sentiment Signal: Sell
Current Market Cap: $42.93M
For detailed information about TELO stock, go to TipRanks’ Stock Analysis page.